-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3309 Gain or Amplification of 1q21 in Systemic Light Chain Amyloidosis Is Associated with Advanced Mayo Stage, Plasma Cell Disease and Worse Overall Survival

Program: Oral and Poster Abstracts
Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Plasma Cell Disorders, Diseases, Lymphoid Malignancies
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Sara Oubari, MD.1*, Maria Papathanasiou2*, Lars Christian Michel3*, Tienush Rassaf4*, Andreas Thimm4*, Tim Hagenacker4*, Daniela Ehling5*, Stefan Wieczorek5*, Eyad Naser4*, Ulrich Duehrsen, MD6*, Hans Christian Reinhardt, MD7 and Alexander Carpinteiro8*

1Department of hematology and stem cell transplantation, University Hospital Essen, Essen, Germany
2Department of Cardiology and Angiology, University Hospital Frankfurt, Frankfurt, DEU
3University Hospital Essen, Essen, North-Rhine Westphalia, DEU
4University Hospital Essen, Essen, DEU
5Department of Medical Genetics, MVZ Dr. Eberhard & Partner Dortmund, Dortmund, Germany
6Universitaetsklinikum Essen, Klinik Fuer Haematologie, Essen, DEU
7Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
8Department of Hematology and Stem Cell Transplantation, University Hospital of Essen, Essen, DEU

Systemic light chain amyloidosis is an acquired protein misfolding disease characterized by extracellular deposition of misfolded amyloidogenic immunoglobulin light chain fibrils secreted most often from clonal plasma cells in the bone marrow. Interphase fluorescence in situ Hybridization (iFISH) is an essential method to characterize disease biology and to define the treatment approach in multiple myeloma. In this retrospective study we included 169 patients with AL amyloidosis who presented between 2015-2024 and analyzed the role of iFISH aberrations on clinical characteristics and outcome. The most commonly detected aberrations were t(11;14) in 56.2%, deletion 13q14 in 33%, +1q21 in 21%, hyperdiploidy in 20.3% and deletion 16q23 in 16.4%. Significant elevations in dFLC levels were observed in patients with +1q21 (median 406 vs. 208 mg/l, p = 0.02), deletion 16q23 (median 476 vs. 203, p = 0.005), with a trend noted in t(11;14) (median 272 vs. 140 mg/l, p = 0.055). Only +1q21 was significantly associated with increased levels of biomarkers for cardiac damage including NTproBNP (median 8845 vs. 3482 pg/ml, p = 0.002) and hsTnT (median 104 vs. 52 ng/l, p = 0.001). This resulted in an increased proportion of patients with Mayo stage IIIb (53% vs. 26%, p = 0.02). Patients positive for +1q21 also had more advanced plasma cell disease (p = 0.001). In the overall population, +1q21 showed worse overall survival after a median follow-up time of 38 months (p = 0.006). In light of current induction regimens with bortezomib and daratumumab, our study is the first that identifies +1q21 as the main chromosomal aberration that predicts poor survival.

Disclosures: Michel: Bayer: Consultancy; Alnylam: Consultancy; AstraZeneca: Consultancy; Bristol Myers Squibb: Consultancy; Pfizer: Consultancy. Rassaf: Mycor GmbH: Other: co-founder of mycor GmbH. Reinhardt: CDL Therapeutics GmbH: Current equity holder in private company; Gilead: Research Funding; Merck: Consultancy, Honoraria; Vertex: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria; Roche: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria. Carpinteiro: Alexion: Consultancy; Alnylam: Consultancy.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH